Encompass Health Co. (NYSE: EHC – Get Rating ) has a consensus “buy” recommendation from the ten brokerages currently covering the stock, according to Marketbeat. One analyst has assigned a hold rating to the stock, five have assigned a buy rating and one has assigned a strong buy rating to the company. Analysts who have rated the stock in the last year have an average 1-year price target of $64.13.
A number of research firms have recently commented on EHC. TheStreet raised Encompass Health from a “c+” rating to a “b-” rating in a report on Wednesday, December 21st. StockNews.com began coverage on shares of Encompass Health in a report on Wednesday, October 12th. They set a “hold” rating on the stock. Raymond James upped their price target on Encompass Health from $65.00 to $72.00 and gave the company a “strong buy” rating in a report on Friday, October 28th. Finally, Stephens cut their price target on Encompass Health from $60.00 to $58.00 and set an “overweight” rating on the stock in a report on Friday, October 28th.
In other news, Director Greg D. Carmichael purchased 1,830 shares of Encompass Health stock in a trade dated Monday, October 31st. The stock was purchased at an average cost of $54.67 per share for a total transaction value of $100,046.10. After the transaction is completed, the director now directly owns 10,546 shares of company stock, valued at $576,549.82. The purchase was disclosed in a filing with the SEC, which is available on the SEC website. Company insiders own 2.70% of the company.
Institutional inflows and outflows
Several hedge funds and other institutional investors have recently increased or decreased their stakes in EHC. Wipfli Financial Advisors LLC purchased $25,000 worth of new positions at Encompass Health in the third quarter. CWM LLC increased its position in Encompass Health by 67.6% during the third quarter. CWM LLC now owns 625 shares of the company worth $28,000 after acquiring an additional 252 shares last quarter. Worth Asset Management LLC purchased $35,000 worth of new positions at Encompass Health during the first quarter. Eagle Bay Advisors LLC increased its position in Encompass Health by 137.5% during the second quarter. Eagle Bay Advisors LLC now owns 1,019 shares of the company worth $57,000 after acquiring an additional 590 shares last quarter. Finally, SeaCrest Wealth Management LLC purchased $85,000 worth of new positions at Encompass Health during the second quarter. 96.14% of the shares are currently held by hedge funds and other institutional investors.
Encompass Health Trading rose 1.5%
NYSE: EHC opened Friday at $62.25. The company’s current ratio is 1.21, quick ratio is 1.21, and debt-to-equity ratio is 1.59. The market cap is $6.21 billion, with a P/E ratio of 22.89, a P/E ratio of 2.57, and a beta of 1.02. The company’s 50-day moving average is $58.21 and its 200-day moving average is $52.99. Encompass Health had a 12-month low of $44.33 and a 12-month high of $74.61.
Encompass Health (NYSE: EHC – Get Rating ) last reported quarterly earnings results on Wednesday, October 26th. The company reported earnings per share of $0.67 for the quarter, missing analysts’ average estimate of $0.68 ($0.01). The company’s revenue for the quarter was $1.09 billion, compared with the consensus estimate of $1.06 billion. Encompass Health had a return on equity of 15.59% and a net margin of 5.39%. Sell-side analysts expect Encompass Health to report earnings of $2.79 per share this year.
Include Health Company Profile
Encompass Health Corp. is engaged in the provision of post-acute healthcare services. It operates through its Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provide rehabilitation treatment and care for patients with stroke and other neurological disorders, heart and lung disorders, brain and spinal cord injuries, complex orthopedic disorders, and amputations.
This breaking news alert is powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate coverage. This story was reviewed by MarketBeat’s editorial team before publication. Please send any questions or comments about this story to firstname.lastname@example.org.
You’ll want to hear this before you consider Encompass Health.
MarketBeat tracks Wall Street’s highest-rated and top-performing research analysts and the stocks they recommend to clients on a daily basis. MarketBeat has identified five stocks that top analysts are quietly telling their clients to buy right before the broader market hits… and Encompass Health isn’t on the list.
While Encompass Health currently has a “buy” rating among analysts, the top-rated analysts see these five stocks as better buys.
Check out five stocks here